Moteur de recherche d’entreprises européennes
Financement de l’UE (8 007 323 €) : Améliorer l’avenir des soins contre le cancer avec Alpha Theranostics Hor19/09/2024 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Améliorer l’avenir des soins contre le cancer avec Alpha Theranostics
Accelerate.EU, a collaborative European initiative, envisions revolutionising theranostics through innovative targeted alpha-therapies (TATs) using astatine-211. A unique consortium will combine diagnostics with potent cytotoxic effects of alpha-particles to enable precise tumour radiation while minimising side effects. Accelerate.EU's core objectives are: Innovate theranostic solutions based on therapeutic and diagnostic pairs for hard-to-treat cancers, exploring the potential for simultaneous preclinical studies and early-phase clinical trials (i.e. co-clinical approach) to showcase the enhanced benefits of these approaches for cancer patients. • Establish a robust and sustainable EU manufacturing and treatment infrastructure for astatine-211, ensuring compliance with quality assurance and regulatory guidelines while streamlining the supply chain across the EU. • Produce comprehensive educational and training content to support the deployment of theranostic solutions, fostering knowledge dissemination, transfer and longevity/durability Accelerate.EU strategically develop TATs to address unmet clinical needs in pancreatic, breast, and brain cancers. The co-clinical approach, incorporating concurrent clinical and preclinical studies, adds a breakthrough dimension to theranostics. Accelerate.EU pioneers 211At-theranostics establishing a resilient EU scale-up production network and empowering healthcare providers to offer TATs to cancer patients. Through the collaboration of experts from academia, industry and regulatory agencies, Accelerate.EU's implements a visionary approach addressing clinical gaps, accelerating TAT theranostic development, supporting EU global leadership, with primary target to improve patient outcomes for lasting impact on EU cancer care.
| Association Hospitaliere de Bruxelles-Centre Hospitalier Universitaire Jules Bordet | 1 111 919 € |
| ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | 439 250 € |
| FORSCHUNGSZENTRUM JULICH GmbH | 440 750 € |
| Fundacion Centro de Tecnologias de Interaccion Visual y Comunicaciones Vicomtech | 168 150 € |
| Groupement Interet Public Arronax | 739 163 € |
| Institut de Cancerologie de l'Ouest | 469 325 € |
| Institut National de la Sante et de la Recherche Medicale | 389 563 € |
| Ion Beam Applications SA | 1 788 269 € |
| Kobenhavns Universitet | 46 028 € |
| Lablogic Systems Ltd. | 0,00 € |
| Narodowe Centrum Badan Jadrowych | 372 938 € |
| Region Hovedstaden | 336 375 € |
| Studiecentrum Voor Kernenergie / Centre d'Etude de l'Energie Nucleaire | 441 451 € |
| Tetrakit Technologies ApS | 506 100 € |
| THE Oncidium Foundation | 173 750 € |
| Universidade de Coimbra | 286 688 € |
| Universite Libre de Bruxelles | 297 606 € |
https://cordis.europa.eu/project/id/101173001
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.